Tianjin Chase Sun Pharmaceutical Co Ltd Total Assets
Tianjin Chase Sun Pharmaceutical Co Ltd total assets. Based on the latest financial reports, Tianjin Chase Sun Pharmaceutical Co Ltd (300026) holds total assets worth CN¥10.37 Billion CNY (≈ $1.52 Billion USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Tianjin Chase Sun Pharmaceutical Co Ltd (300026) market capitalisation for the company's overall valuation and market capitalisation.
Total Assets of Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
Total assets of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024. This chart illustrates how Tianjin Chase Sun Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 300026 share price today for real-time trading data and today's change.
Tianjin Chase Sun Pharmaceutical Co Ltd - Asset Composition Analysis
Tianjin Chase Sun Pharmaceutical Co Ltd Total Assets Breakdown (December 2024)
Tianjin Chase Sun Pharmaceutical Co Ltd total assets breakdown as of December 2024. Tianjin Chase Sun Pharmaceutical Co Ltd's total assets of CN¥10.37 Billion consist of 55.1% current assets and 44.9% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 11.7% |
| Accounts Receivable | CN¥2.86 Billion | 25.7% |
| Inventory | CN¥1.75 Billion | 15.7% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥634.49 Million | 5.7% |
| Goodwill | CN¥675.20 Million | 6.1% |
Asset Composition Trend (2006–2024)
This chart illustrates how Tianjin Chase Sun Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore 300026 working capital efficiency to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Tianjin Chase Sun Pharmaceutical Co Ltd's current assets represent 55.1% of total assets in 2024, an increase from 43.2% in 2006.
- Cash Position: Cash and equivalents constituted 11.7% of total assets in 2024, up from 4.8% in 2006.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 11.0% of total assets, a decrease from 16.0% in 2006.
- Asset Diversification: The largest asset category is accounts receivable at 25.7% of total assets.
Tianjin Chase Sun Pharmaceutical Co Ltd Competitors by Total Assets
Key competitors of Tianjin Chase Sun Pharmaceutical Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276
|
China | CN¥68.33 Billion |
|
Sandoz Group AG
SW:SDZ
|
Switzerland | CHF22.86 Billion |
|
H Lundbeck A/S
CO:HLUN-B
|
Denmark | Dkr54.01 Billion |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥30.77 Billion |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
|
China | CN¥17.01 Billion |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518
|
China | CN¥13.68 Billion |
|
Viyash Scientific Limited
NSE:SEQUENT
|
India | Rs17.26 Billion |
|
Anhui Fengyuan Pharmaceutical Co Ltd
SHE:000153
|
China | CN¥5.11 Billion |
Tianjin Chase Sun Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.70 | 4.03 | 2.85 |
| Quick Ratio | 3.62 | 2.88 | 2.14 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.52 Billion | CN¥4.57 Billion | CN¥3.84 Billion |
Tianjin Chase Sun Pharmaceutical Co Ltd - Advanced Valuation Insights
This section examines the relationship between Tianjin Chase Sun Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.05 |
| Latest Market Cap to Assets Ratio | 0.13 |
| Asset Growth Rate (YoY) | -5.7% |
| Total Assets | CN¥11.17 Billion |
| Market Capitalization | $1.42 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Tianjin Chase Sun Pharmaceutical Co Ltd's assets below their book value (0.13x), which may indicate investor concerns about asset quality or future growth.
Significant Asset Reduction: Tianjin Chase Sun Pharmaceutical Co Ltd's assets decreased by 5.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Tianjin Chase Sun Pharmaceutical Co Ltd (2006–2024)
The table below shows the annual total assets of Tianjin Chase Sun Pharmaceutical Co Ltd from 2006 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥11.17 Billion ≈ $1.63 Billion |
-5.66% |
| 2023-12-31 | CN¥11.84 Billion ≈ $1.73 Billion |
-6.30% |
| 2022-12-31 | CN¥12.63 Billion ≈ $1.85 Billion |
+8.82% |
| 2021-12-31 | CN¥11.61 Billion ≈ $1.70 Billion |
+14.02% |
| 2020-12-31 | CN¥10.18 Billion ≈ $1.49 Billion |
+20.80% |
| 2019-12-31 | CN¥8.43 Billion ≈ $1.23 Billion |
+12.60% |
| 2018-12-31 | CN¥7.48 Billion ≈ $1.10 Billion |
+0.75% |
| 2017-12-31 | CN¥7.43 Billion ≈ $1.09 Billion |
+2.02% |
| 2016-12-31 | CN¥7.28 Billion ≈ $1.07 Billion |
+12.49% |
| 2015-12-31 | CN¥6.47 Billion ≈ $947.14 Million |
+112.68% |
| 2014-12-31 | CN¥3.04 Billion ≈ $445.35 Million |
+37.15% |
| 2013-12-31 | CN¥2.22 Billion ≈ $324.71 Million |
+23.15% |
| 2012-12-31 | CN¥1.80 Billion ≈ $263.66 Million |
+28.02% |
| 2011-12-31 | CN¥1.41 Billion ≈ $205.96 Million |
+9.97% |
| 2010-12-31 | CN¥1.28 Billion ≈ $187.28 Million |
+20.54% |
| 2009-12-31 | CN¥1.06 Billion ≈ $155.37 Million |
+388.98% |
| 2008-12-31 | CN¥217.14 Million ≈ $31.77 Million |
+24.06% |
| 2007-12-31 | CN¥175.03 Million ≈ $25.61 Million |
+65.72% |
| 2006-12-31 | CN¥105.62 Million ≈ $15.46 Million |
-- |
About Tianjin Chase Sun Pharmaceutical Co Ltd
Tianjin Chase Sun Pharmaceutical Co.,Ltd engages in the research and development, production, and sale of various pharmaceutical products in China and internationally. The company provides Chinese medicine formula granules, finished drugs, raw materials, medical devices and excipients, medical and health services, as well as smart supply chain for pharmaceuticals and medical devices. It serves th… Read more